Search results for "Progression"

showing 10 items of 1251 documents

The impact of aircraft noise on vascular and cardiac function in relation to noise event number: a randomized trial

2020

Abstract Aims Nighttime aircraft noise exposure has been associated with increased risk of hypertension and myocardial infarction, mechanistically linked to sleep disturbance, stress, and endothelial dysfunction. It is unclear, whether the most widely used metric to determine noise exposure, equivalent continuous sound level (Leq), is an adequate indicator of the cardiovascular impact induced by different noise patterns. Methods and results In a randomized crossover study, we exposed 70 individuals with established cardiovascular disease or increased cardiovascular risk to two aircraft noise scenarios and one control scenario. Polygraphic recordings, echocardiography, and flow-mediated dila…

MaleTime FactorsAircraft noiseAircraftBrachial ArteryPhysiologyDenmark030204 cardiovascular system & hematologyVentricular Function Leftlaw.invention0302 clinical medicineRandomized controlled triallawDiastoleAcademicSubjects/MED00200030212 general & internal medicineMyocardial infarctionEndothelial dysfunctionAircraft noise exposureSleep disorderCross-Over StudiesMiddle AgedEchocardiography DopplerIrritable MoodFlow-mediated dilationVasodilationEnvironmental healthCardiovascular DiseasesNoise TransportationCardiologyDisease ProgressionFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyRisk in Cardiovascular DiseaseDiastoleSleep disturbance03 medical and health sciencesDouble-Blind MethodPhysiology (medical)Internal medicinemedicinePressureHumansAgedbusiness.industryCardiac functionStroke VolumeOriginal ArticlesVascular functionmedicine.diseaseCrossover studybusinessCardiovascular Research
researchProduct

Heme oxygenase-1 regulates the progression of K/BxN serum transfer arthritis.

2012

Background Heme oxygenase-1 (HO-1) is induced in many cell types as a defense mechanism against stress. We have investigated the possible role of endogenous HO-1 in the effector phase of arthritis using the K/BxN serum transfer model of arthritis in HO-1 heterozygous and homozygous knock-out mice. Methodology/Principal Findings Arthritis was induced in C57/Black-6 xFVB (HO-1+/+, HO-1+/− and HO-1−/−) mice by intraperitoneal injection of 150 µl serum from arthritic K/BxN mice at days 0 and 2. Blood was collected and animals were sacrificed at day 10. Histological analysis was performed in ankle sections. The levels of inflammatory mediators were measured in serum and paw homogenates by enzyme…

MaleTime FactorsAnatomy and PhysiologyMouseNon-Clinical MedicineArthritislcsh:MedicineEndogenyBiochemistryAntioxidantsMicechemistry.chemical_compoundDrug Discoverylcsh:ScienceMusculoskeletal SystemHemeRegulation of gene expressionMultidisciplinaryEffectorSystems BiologyAnimal ModelsEnzymesDisease ProgressionMedicineMatrix Metalloproteinase 3Inflammation Mediatorsmedicine.symptomResearch ArticleCell typeOsteocalcinRheumatoid ArthritisInflammationModel OrganismsRheumatologymedicineAnimalsBiologyBlood CellsRANK Ligandlcsh:Rmedicine.diseaseArthritis ExperimentalMolecular biologyMice Inbred C57BLHeme oxygenaseDisease Models AnimalGene Expression RegulationchemistryImmunologylcsh:QAnkle JointHeme Oxygenase-1PLoS ONE
researchProduct

Task force on 'Early markers of atherosclerosis: influence of age and sex'

2013

Atherosclerosis and its complications are the most important causes of death all over the world, especially in Western countries. Diet habits, modern stress life, smoking, sedentary way of life and an involvement of genetic pattern of individuals lead to a sure degeneration of quality of life increasing the risk of atherosclerosis development. For this reason, the main purpose of actual medicine is to identify all the markers that could allow the physicians to evaluate the first moments of the development of this dangerous pathological process. The aim is to reduce the speed of its evolution, trying to delay indefinitely the risk coming from the morphological alterations of the vessels. 'En…

MaleTime FactorsCarotid Intima-Media ThicknessSex FactorsVascular StiffnessPredictive Value of TestsRisk FactorsHumansAorta AbdominalEarly markers of atherosclerosis age sexAge FactorsbiomarkersGenderatherosclerosis; gender differencesPrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareVasodilationEarly Diagnosisatherosclerosis; biomarkers; Gender; ageingageingDisease ProgressionFemaleEndothelium VascularatherosclerosisDilatation Pathologic
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study

2018

The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC).

MaleTime Factorsmedicine.medical_treatment:Medicina Básica [Ciências Médicas]Treatment outcomeBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumor; Aged; Aged 80 and over; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Progression-Free Survival; Recurrence; Regression Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-grade80 and overAged 80 and overTransurethral resection of bladder tumorCARCINOMA TRANSITIONAL CELLHigh riskBladder cancerFollow up studiesMiddle AgedPrognosisProgression-Free Survival3. Good healthScholarshipTreatment OutcomeLocal030220 oncology & carcinogenesisCiências Médicas::Medicina BásicaUrinary Bladder NeoplasmDisease ProgressionRegression AnalysisUrologic Surgical ProceduresFemaleSecond look resectionHumanmedicine.medical_specialtyTime FactorPrognosiUrologyBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumorCystectomyRegression AnalysiDisease-Free SurvivalResectionFollow-Up StudieCystectomy03 medical and health sciencesbladder cancer; high risk; high-grade; second look resection; transurethral resection of bladder tumor; aged; aged 80 and over; carcinoma transitional cell; cystectomy; disease progression; disease-free survival; female; follow-up studies; humans; malemedicineHumansProgression-free survivalAgedCarcinoma Transitional CellScience & Technologybusiness.industryGeneral surgeryDisease progressionCarcinomaNeoplasm RecurrenceUrinary Bladder NeoplasmsUrologic Surgical ProcedureTransitional CellTransurethral resection of bladder tumor.Neoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin

2009

The dual role of the inducible NO synthase (iNOS) and NO signaling in head and neck squamous cell carcinoma (HNSCC) is a complex and can both promote or inhibit tumor progression. However, the underlying molecular mechanisms are not yet resolved in detail. We show for the first time that conditions, favoring low NO levels conferred resistance against cisplatin/taxol-induced apoptosis in HNSCC cell lines. Cytoprotection was mediated by survivin, because we observed its upregulation subsequent to low doses of the NO donors S-nitroso-N-acetyl-penicillamine (SNAP) and sodium nitroprusside (SNP) or ectopic expression of physiologic amounts of iNOS. Also, RNAi-mediated depletion of survivin block…

MaleUmbilical VeinsCancer ResearchSurvivinFluorescent Antibody TechniqueNitric Oxide Synthase Type IIApoptosisp38 Mitogen-Activated Protein KinasesInhibitor of Apoptosis ProteinsImmunoenzyme TechniquesPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundLY294002Enzyme InhibitorsRNA Small InterferingAged 80 and overReverse Transcriptase Polymerase Chain ReactionCell CycleMiddle AgedCell cycleOncologyHead and Neck NeoplasmsCarcinoma Squamous CellFemaleMicrotubule-Associated ProteinsNitroprussidePaclitaxelImmunoblottingAntineoplastic AgentsS-Nitroso-N-AcetylpenicillamineBiologyCell LineDownregulation and upregulationSurvivinmedicineHumansNitric Oxide DonorsRNA MessengerneoplasmsProtein kinase BNitritesPI3K/AKT/mTOR pathwayAgedmedicine.diseaseAntineoplastic Agents PhytogenicHead and neck squamous-cell carcinomachemistryDrug Resistance NeoplasmTumor progressionImmunologyCancer researchEndothelium VascularCisplatinProto-Oncogene Proteins c-aktInternational Journal of Cancer
researchProduct

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

2019

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS). Methods: This was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS we…

MaleVital CapacityPilot ProjectsGastroenterologylaw.inventionPlacebos0302 clinical medicineRandomized controlled triallawStilbenesMedicineAmyotrophic lateral sclerosisMedicamento1-(beta-D-Ribofuranosyl)nicotinamide chlorideMiddle AgedDrug CombinationsTreatment OutcomeNeurologyTolerabilityDisease ProgressionFemale35-Dimethoxy-4′-hydroxy-trans-stilbeneNiacinamidemedicine.medical_specialty3Investigación médicaPlaceboDouble blind03 medical and health sciencesAtrophyDouble-Blind MethodInternal medicinerandomized control studyHumansMuscle StrengthhumanAgedElectromyographybusiness.industryAmyotrophic Lateral Sclerosismedicine.diseaseAmyotrophic lateral sclerosis5-Dimethoxy-4 '-hydroxy-trans-stilbeneMétodo doble ciego1-(beta-D-Ribofuranosyl) nicotinamide chlorideRibonucleosidesNeurology (clinical)business030217 neurology & neurosurgeryEsclerosis amiotrófica lateral
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct